青壮年强直性脊柱炎骨代谢类型对临床预防及治疗意义的研究

邹玉琼; 张莹莹; 李涯松

doi:10.16766/j.cnki.issn.1674-4152.002086

青壮年强直性脊柱炎骨代谢类型对临床预防及治疗意义的研究

doi: 10.16766/j.cnki.issn.1674-4152.002086

浙江省人民医院杭州医学院附属人民医院风湿免疫科，浙江杭州 310014

基金项目:

浙江省中医药科技计划项目 2018ZB009

浙江省中医药重点研究项目 2016ZZ006

详细信息

通讯作者:
李涯松, E-mail: lysong2@163.com

中图分类号: R593.23 R446
计量
- 文章访问数: 127
- HTML全文浏览量: 65
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-18
- 网络出版日期: 2022-02-15

Study on the clinical significance of bone metabolism types in young adult patients with ankylosing spondylitis

Department of Rheumatology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, China

摘要

摘要: 目的探讨青壮年活动期强直性脊柱炎(AS)骨代谢类型与骨密度之间的关系，为临床青壮年AS骨密度下降者的预防及治疗提供依据。方法纳入2015年2月—2020年11月在浙江省人民医院就诊的AS患者103例，分析不同骨代谢类型与骨密度的相关性。结果入组的103例AS患者，骨密度正常组49例，骨密度低下组54例。骨密度低下组患者Ⅰ型胶原羧基端肽β特殊序列(β-CTX)、N端骨钙素(OC)、总Ⅰ型胶原氨基端前肽(P1NP)的均值均显著高于骨密度正常组(均P＜0.001)。骨密度低下组又分为低中转换组(28例)和高转换组(26例)。高转换组的股骨颈骨密度T值为-1.56±0.82，显著性低于中低转换组(-1.01±0.92，P=0.029)。2组腰椎的骨密度T值比较差异无统计学意义(P=0.080)。对于不同骨代谢类型治疗前后比较发现：在中低转换组，治疗后股骨颈骨密度值[(0.92±0.09)g/cm²]较治疗前[(0.89±0.08)g/cm²]显著改善(P=0.022)；而在高转换组，治疗后股骨颈骨密度值较治疗前差异无统计学意义(P=0.080)。结论青壮年AS骨密度下降患者血清β-CTX、OC、P1NP明显升高，表现为高转换骨丢失；中低转换的骨密度下降患者通过积极基础病炎症控制，骨密度可以得到有效提升；但是，高转换骨密度下降患者治疗后骨量无显著提升，应探索更为有效的治疗方案。
- 强直性脊柱炎 /
- 骨代谢标志物 /
- 骨代谢类型 /
- 骨密度
Abstract: Objective To investigate the relationship between bone metabolism and bone mineral density in young adults with active ankylosing spondylitis (AS) and to provide a basis for the prevention and treatment of bone mineral density decline in these patients. Methods A total of 103 patients with AS who were treated in our hospital from February 2015 to November 2020 were enrolled in the study. The correlation between different bone metabolism types and bone mineral density was analysed. Results Forty-nine patients had normal BMD, and 54 patients had low BMD. In the low BMD group, the mean values of type I collagen cross-linked C-telopeptide β-collagen specific sequence (β-CTX), osteocalcin (OC) and N-terminal propeptide of type I precollagen (P1NP) were significantly higher than those in the normal BMD group (P < 0.001). The low BMD group was divided into low to moderate and high conversion groups. The T value of femoral neck BMD in the high conversion group was -1.56±0.82, which was significantly lower than that in the low to medium conversion group (-1.01±0.92, P=0.029). However, no significant difference was found in T value of lumbar BMD between the two groups (P=0.080). In the low to medium conversion group, the BMD of femoral neck [(0.92±0.09) g/cm²] after treatment was significantly improved compared with that before treatment [(0.89±0.08) g/cm², P=0.022]. However, in the high conversion group, no significant difference in BMD of femoral neck was found after the treatment (P=0.080). Conclusion The serum levels of β-CTX, OC and P1NP are significantly increased in young adult patients with decreased bone mineral density, showing high loss of bone turnover high conversion bone loss. Patients with low to moderate conversion of bone mineral density reduction can be effectively treated through active basic disease inflammation control. However, more effective treatments should be explored for patients with high conversion of bone mineral density reduction.
- Ankylosing spondylitis /
- Markers of bone metabolism /
- Types of bone metabolism /
- Bone mineral density

HTML全文

表 1 2组AS患者骨代谢标志物结果比较(x±s)

组别	例数	β-CTX(pg/mL)	OC(ng/mL)	P1NP(ng/mL)	25-羟维生素D₃(ng/mL)	甲状旁腺素(pg/mL)
骨密度正常组	49	293.50±89.61	15.27±4.28	44.76±13.89	18.69±5.91	40.57±17.29
骨密度低下组	54	529.42±345.96	24.05±14.40	71.92±50.28	19.50±7.37	40.69±39.23
t值		4.836	4.281	3.812	0.613	0.020
P值		＜0.001	＜0.001	＜0.001	0.542	0.984

下载: 导出CSV

表 2 中低转换组和高转换组骨密度低下AS患者骨密度T值比较(x±s)

组别	例数	股骨颈骨密度T值	腰椎(L_1~4)骨密度T值
中低转换组	28	-1.01±0.92	-1.01±0.90
高转换组	26	-1.56±0.82	-1.50±1.05
t值		2.242	1.815
P值		0.029	0.080

下载: 导出CSV

表 3 2组骨密度低下AS患者治疗前后骨密度比较(x±s，g/cm²)

组别	例数	股骨颈骨密度		t值	P值	腰椎骨密度		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
中低转换组	10	0.89±0.08	0.92±0.09	-2.917	0.022	0.91±0.11	0.93±0.12	-0.845	0.426
高转换组	10	0.74±0.06	0.80±0.10	-1.971	0.080	0.87±0.11	0.93±0.10	-2.604	0.029
t值		-4.623	-2.534			-0.910	0.036
P值		＜0.001	0.021			0.377	0.972

下载: 导出CSV

参考文献(18)

[1]	胡劲涛, 柴乐, 任伟凡, 等. 强直性脊柱炎骨代谢的研究进展[J]. 中国骨质疏松杂志, 2019, 25(6): 875-879. doi: 10.3969/j.issn.1006-7108.2019.06.031
[2]	MAGREY M N, LEWIS S, ASIM KHAN M, et al. Utility of DX-A scanning and risk factors for osteoporosis in ankylosing spondylitis-A prospective study[J]. Semin Arthritis Rheum, 2016, 46(1): 88-94. doi: 10.1016/j.semarthrit.2016.03.003
[3]	WANG D M, ZENG Q Y, CHEN S B, et al. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: A 5-year follow-up study of 504 cases[J]. Clin Exp Rheumatol, 2015, 33(4): 465-470. http://www.ncbi.nlm.nih.gov/pubmed/25962324
[4]	钟驾云, 吴歆, 徐沪济. 强直性脊柱炎合并骨质疏松或骨量减少临床研究进展[J]. 诊断学理论与实践, 2019, 18(1): 1109-1112. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDLS201901038.htm
[5]	YOON B H, YU W. Clinical utility of biochemical marker of bone turnover: Fracture risk prediction and bone healing[J]. J Bone Metab, 2018, 25(2): 73-78. doi: 10.11005/jbm.2018.25.2.73
[6]	ARCEO-MENDOZA R M, CAMACHO P. Prediction of fracture risk in patients with osteoporosis: a brief review[J]. Womens Health(Lond), 2015, 11(4): 477-484. http://www.onacademic.com/detail/journal_1000038319582410_1e44.html
[7]	边平达, 寿张轩, 李秀央, 等. 骨转换标志物在高龄男性骨密度变化中的预测价值[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(2): 155-159. https://www.cnki.com.cn/Article/CJFDTOTAL-GUSS201802010.htm
[8]	张萌萌, 张秀珍, 邓伟民, 等. 骨代谢生化指标临床应用专家共识(2019)[J]. 中国骨质疏松杂志, 2019, 25(10): 1357-1372. doi: 10.3969/j.issn.1006-7108.2019.10.001
[9]	刘胜峰, 金玮, 杜玉珍. 上海临港地区健康人群骨代谢标志物β-CTx和tP1NP参考区间的建立[J]. 检验医学与临床, 2018, 15(20): 3121-3124. doi: 10.3969/j.issn.1672-9455.2018.20.037
[10]	陈德才, 廖二元, 徐苓骨, 等. 骨代谢生化标志物临床应用指南[J]. 中华骨质疏松和骨矿盐疾病杂志, 2015, 8(4): 283-293. doi: 10.3969/j.issn.1674-2591.2015.04.001
[11]	范晓云, 李志军. 强直性脊柱炎的诊断与治疗[J]. 中华全科医学, 2020, 18(8): 1256-1257. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202008002.htm
[12]	MALOCHET-GUINAMAND S, PEREIRA B, TATAR Z, et al. Preva-lence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures[J]. BMC Musculoskelet Disord, 2017, 18(1): 357. doi: 10.1186/s12891-017-1718-7
[13]	MAAS F, SPOORENBERG A, VAN DER SLIK B P G, et al. Clinical risk factors for the presence and development of vertebral fractures in patients with ankylosing spondylitis[J]. Arthritis Care Res(Hoboken), 2017, 69(5): 694-702. doi: 10.1002/acr.22980
[14]	HENRIKSEN K, CHRISTIANSEN C, KARSDAL M A. Role of biochemical markers in the management of osteoporosis[J]. Climacteric, 2015, 18(Suppl 2): 10-18.
[15]	KOBAVASHI Y, UEHARA S, UDAGAWA N. Roles of non-canonical Wnt signaling pathways in bone resorption[J]. J Oral Biosci, 2018, 60(2): 31-35. doi: 10.1016/j.job.2018.03.001
[16]	王晓林, 曾凡伟, 陈芳. 强直性脊柱炎发生脊柱骨折的危险因素及与骨代谢指标相关性分析[J]. 实用医院临床杂志, 2020, 17(3): 218-221. https://www.cnki.com.cn/Article/CJFDTOTAL-YYLC202003065.htm
[17]	LIU K G, HE Q H, TAN J W, et al. Expression of TNF-alpha, VEGF, and MMP-3 mRNAs in synovial tissues and their roles in fibroblast-mediated osteogenesis in ankylosing spondylitis[J]. Genet Mol Res, 2015, 14(2): 6852-6858. doi: 10.4238/2015.June.18.28
[18]	YANG C, DING P, WANG Q, et al. Inhibition of complement retards ankylosing spondylitis progression[J]. Sci Rep, 2016, 6: 34643. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048143/pdf/srep34643.pdf